Norges Bank Bei Gene, Ltd. Transaction History

Norges Bank

$716 Trillion
Q3 2024

31 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$158.67 - $201.58 $4.36 Million - $5.54 Million	27,477 New	27,477 $4.96 Million
Q3 2023 Nov 13, 2024	BUY	$179.87 - $225.13 $9.71 Million - $12.2 Million	54,000 New	54,000 $9.71 Million
Q3 2023 Nov 13, 2023	SELL	$179.87 - $225.13 $9.71 Million - $12.2 Million	-54,000 Closed	0 $0
Q2 2023 Aug 14, 2024	BUY	$178.3 - $266.78 $9.63 Million - $14.4 Million	54,000 New	54,000 $9.63 Million
Q1 2023 May 15, 2024	BUY	$215.53 - $274.5 $11.6 Million - $14.8 Million	54,000 New	54,000 $11.6 Million
Q4 2022 Feb 14, 2023	BUY	$125.51 - $229.3 $6.78 Million - $12.4 Million	54,000 New	54,000 $11.9 Million
Q3 2022 Nov 13, 2023	BUY	$131.8 - $202.24 $7.12 Million - $10.9 Million	54,000 New	54,000 $7.28 Million
Q1 2022 May 09, 2022	SELL	$146.52 - $269.56 $50.7 Million - $93.4 Million	-346,341 Closed	0 $0
Q4 2021 Mar 09, 2022	BUY	$248.56 - $389.34 $86.1 Million - $135 Million	346,341 New	346,341 $93.8 Million
Q3 2021 Nov 14, 2022	BUY	$249.6 - $403.14 $86.4 Million - $140 Million	346,341 New	346,341 $126 Million
Q3 2021 Nov 05, 2021	SELL	$249.6 - $403.14 $3.66 Million - $5.91 Million	-14,666 Closed	0 $0
Q2 2021 Aug 15, 2022	BUY	$292.75 - $367.01 $4.29 Million - $5.38 Million	14,666 New	14,666 $5.03 Million
Q1 2020 May 08, 2020	SELL	$121.84 - $173.19 $49.6 Million - $70.5 Million	-406,908 Closed	0 $0
Q4 2019 Mar 03, 2020	BUY	$115.78 - $208.34 $47.1 Million - $84.8 Million	406,908 New	406,908 $67.4 Million
Q4 2019 Feb 12, 2020	SELL	$115.78 - $208.34 $47.1 Million - $84.8 Million	-406,908 Closed	0 $0
Q3 2019 Nov 13, 2020	BUY	$120.61 - $148.29 $49.1 Million - $60.3 Million	406,908 New	406,908 $49.8 Million
Q3 2019 Nov 08, 2019	SELL	$120.61 - $148.29 $49.1 Million - $60.3 Million	-406,908 Closed	0 $0
Q2 2019 Aug 13, 2020	BUY	$113.99 - $146.86 $46.4 Million - $59.8 Million	406,908 New	406,908 $50.4 Million
Q2 2019 Aug 09, 2019	SELL	$113.99 - $146.86 $46.4 Million - $59.8 Million	-406,908 Closed	0 $0
Q1 2019 May 11, 2020	BUY	$122.82 - $151.83 $8.12 Million - $10 Million	66,122 Added 19.4%	406,908 $53.7 Million
Q4 2018 Mar 04, 2019	BUY	$107.01 - $175.15 $36.5 Million - $59.7 Million	340,786 New	340,786 $47.8 Million
Q4 2018 Feb 08, 2019	SELL	$107.01 - $175.15 $36.5 Million - $59.7 Million	-340,786 Closed	0 $0
Q3 2018 Nov 12, 2019	BUY	$152.62 - $189.66 $52 Million - $64.6 Million	340,786 New	340,786 $58.7 Million
Q3 2018 Nov 09, 2018	SELL	$152.62 - $189.66 $52 Million - $64.6 Million	-340,786 Closed	0 $0
Q2 2018 Aug 12, 2019	BUY	$152.5 - $216.77 $52 Million - $73.9 Million	340,786 New	340,786 $52.4 Million
Q2 2018 Jul 23, 2018	SELL	$152.5 - $216.77 $42.7 Million - $60.7 Million	-280,047 Closed	0 $0
Q1 2018 May 15, 2019	BUY	$97.41 - $177.22 $27.3 Million - $49.6 Million	280,047 New	280,047 $47 Million
Q1 2018 May 09, 2018	SELL	$97.41 - $177.22 $10.5 Million - $19.1 Million	-107,512 Closed	0 $0
Q4 2017 Mar 05, 2018	BUY	$79.6 - $114.73 $8.56 Million - $12.3 Million	107,512 New	107,512 $10.5 Million
Q4 2017 Feb 09, 2018	SELL	$79.6 - $114.73 $3.44 Million - $4.96 Million	-43,233 Closed	0 $0
Q3 2017 Nov 13, 2018	BUY	$66.19 - $103.46 $2.86 Million - $4.47 Million	43,233	43,233 $4.47 Million

Others Institutions Holding BGNE

# of Institutions

252

Shares Held

45.3M

Call Options Held

292K

Put Options Held

119K

Baker Bros. Advisors LP New York, NY

10.6M
Shares

$1.91 Billion
25.41% of portfolio
Capital International Investors Los Angeles, CA

6.43M
Shares

$1.16 Billion
0.29% of portfolio
Hhlr Advisors, Ltd. Grand Cayman, E9

5.18M
Shares

$935 Million
26.65% of portfolio
Primecap Management CO Pasadena, CA

4.97M
Shares

$899 Million
0.84% of portfolio
Baillie Gifford & CO

3.71M
Shares

$669 Million
0.64% of portfolio

View Full List

About BeiGene, Ltd.

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $18.7B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

More about BGNE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Account